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Erythrocyte glucose-6-phosphate dehydrogenase deficiency in male newborn
babies and its relationship with neonatal jaundice
Deficiência de glicose-6-fosfato desidrogenase eritrocitária em recém-nascidos do sexo masculino e
sua relação com a icterícia neonatal
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Glucose-6-phosphate dehydrogenase (G6PD) deficiency, the commonest red cell
enzymopathy in humans, has an X-linked inheritance. The major clinical manifestations
are drug induced hemolytic anemia, neonatal jaundice and chronic nonspherocytic
hemolytic anemia. The incidence of neonatal hyperbilirubinemia is much greater in
G6PD-deficient neonates than babies without this deficiency. The aim of this study was
to ascertain the presence of neonatal jaundice in erythrocyte G6PD-deficient male
newborns. Samples of umbilical cord blood from a total of 204 male newborns of the
Januário Cicco School Maternity located in Natal, Rio Grande do Norte, Brazil were
analyzed. The G6PD deficiency was identified by the methemoglobin reduction test
(Brewer's test). The deficiency was confirmed by quantitative spectrophotometric assay
for enzyme activity and cellulose acetate electrophoresis was used to identify the G6PD
variant. Eight newborns were found to be G6PD deficient with four of them exhibiting
jaundice during the first 48 hours after birth with bilirubin levels higher than 10 mg/dL.
All deficient individuals presented the G6PD A- variant at electrophoresis. Our findings
confirmed the association between G6PD deficiency and neonatal jaundice. Hence,
early diagnosis of the deficiency at birth is essential to control the appearance of jaundice
and to prevent the exposure of these newborns to known hemolytic agents.
Keywords:  Glucosephosphate dehydrogenase; infant, newborn; jaundice;
hyperbilirubinemia.
Universidade Federal do Rio Grande do Norte (UFRN) – Natal-RN.
1Farmacêutica bioquímica. Universidade Federal do Rio Grande do Norte (UFRN) – Natal-RN.
2Médica. Maternidade Escola Januário Cicco. Universidade Federal do Rio Grande do Norte (UFRN) – Natal-RN.
3Médica. Professor Adjunto do Departamento de Pediatria da Universidade Federal do Rio Grande do Norte (UFRN) – Natal-RN.
4Aluna do Curso de Farmácia da Universidade Federal do Rio Grande do Norte (UFRN) – Natal-RN.
5Médico. Professor Associado da Faculdade de Medicina da Universidade de São Paulo (FMUSP) – São Paulo-SP.
6Farmacêutica bioquímica. Professor Adjunto do Depto. de Análises Clínicas e Toxicológicas (UFRN) – Natal-RN.
Suporte financeiro: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Apoio à Pesquisa do Estado do Rio
Grande do Norte (Fapern) – Edital “Programa Pesquisa para o SUS RN 2004” (Convênio nº 0146.00/04-CNPq/Fapern/SUS), Fundo de Apoio à
Pesquisa em Alimentos e Medicamentos da Universidade Federal do Rio Grande do Norte (Fapam/UFRN).
Conflito de interesse: sem conflito de interesse
Recebido: 14/10/2009
Aceito após modificações: 09/05/2010
Correspondência: Tereza Maria Dantas de Medeiros
Departamento de Análises Clínicas e Toxicológicas – UFRN
Rua General Cordeiro de Farias, s/n – 1º andar
59010-180 – Natal-RN – Brasil
Tel.:/Fax.: (55 84) 3342-9796
E-mail: tdantas@ufrnet.br
REVISTA BRASILEIRA DE
HEMATOLOGIA E  H E M O T E R A P I A
435
Introduction
Glucose 6-phosphate dehydrogenase (G6PD) is a
constitutive enzyme that is expressed in all tissues. It catalyzes
glucose-6-phosphate oxidation to 6-phosphogluconolactone
and converts the coenzyme nicotinamide adenine
dinucleotide phosphate to its reduced form (NADPH). The
hexosemonophosphate pathway is the only source of
NADPH in red blood cells.1 NADPH is used to reduce oxidized
glutathione to its reduced form (GSH), which is very important
to reduce peroxide and other reactive oxygen species by
glutathione reductase. NADPH also activates catalase,
which, in turn, reduces peroxides.2
G6PD deficiency was first described in black
individuals who were given primaquine to treat malaria and
presented jaundice, thereby launching the hematological field
of erythroenzymopathies. G6PD deficiency is by far the most
prevalent erythroenzymopathy, affecting more than 400
million people throughout the world, in particular in Africa,
Mediterranean countries and Southwest Asia. The G6PD gene
is located in the long arm of chromosome X (Xq 28), with 13
exons and 12 introns.1 As G6PD is X linked, its deficiency
mainly affects men (hemizygosity) as they have just one X
chromosome and thus suffer low enzyme activity and
hemolysis when exposed to hemolytic agents. On the other
hand, women may be heterozygotes, presenting with one
normal and one deficient allele and thus with intermediary
enzyme activity or homozygotes when both alleles are
affected.3
Most of deficient individuals are asymptomatic and may
exhibit neonatal jaundice or hemolysis when oxidative stress
is triggered by drugs, infections or broad beans (fava).
Chronic nonspherocytic hemolytic anemia is much less
common.1,3
The incidence of neonatal hyperbilirubinemia is much
greater in G6PD-deficient neonates than in babies without
this deficiency. However, this incidence may vary between
ethnic groups and geographic regions. The clinical
manifestation of neonatal jaundice related to G6PD deficiency
is not very common at birth but often appears from one to
four days after birth and requirs phototherapy in order to
avoid kernicterus. Nevertheless, neonatal jaundice can be
very severe in G6PD-deficient neonates, especially when
associated with prematurity, infection, maternal exposure to
oxidant drugs and environmental factors such as naphthalene-
camphor mothballs.1,4
In Brazil the relationship between G6PD deficiency and
neonatal jaundice has been little studied, but even so
controversial results have been published as the association
was found in São Paulo State,5,6,7  but not in the State of
Bahia.8
The aim of this work was to ascertain the presence of
neonatal jaundice in erythrocyte G6PD-deficient male
newborns.
 Material and Methods
From May 2004 to December 2005, a cross-sectional
study analyzed 204 umbilical cord blood samples of male
newborns from the Januário Cicco School Maternity located
in Natal, Rio Grande do Norte, Brazil. The survey was
approved by the Ethics Committee of the Federal University
of Rio Grande do Norte and all mothers signed an informed
consent form.
Newborns weighing more than 2500g, born from non-
diabetic pregnant women were studied. The gestational age
was assessed by the records of prenatal care units and
confirmed after birth according to Capurro method.9 Preterm
newborns were also excluded. Reports have shown that
newborns of diabetic mothers and premature newborns may
suffer from hyperbilirubinemia.10,11,12
Weight and Apgar score were noted as was the maternal
ethnic group based upon skin color, hair, and nose and lips
shape. Special attention was paid to any medicines given to
the mother and her newborn as well as any naphthalene or
nitrites impregnation of the mother's clothes.
Umbilical cord blood samples were collected after
umbilical cord clamping in tubes containing ACD (citric acid,
citrate and dextrose) and kept at 4°C for a maximum of 24
hours before performing laboratory tests. All samples were
tested by the methemoglobin reduction test (Brewer's test).13
G6PD deficiency screened by the Brewer's test was confirmed
in blood obtained by venous puncture and analyzed by
quantitative spectrophotometric assay for enzyme activity.14
G6PD activity was expressed in international units per gram
of hemoglobin per minute at 37ºC (IU/gHb/min at 37°C). A
mean of 12.9 ± 2.4 IU/gHb/min at 37°C was considered to be
the normal reference value. Cellulose acetate electrophoresis
was performed in order to identify the G6PD variant.15
All newborns were examined at 12-hour intervals by a
neonatologist for any signs of jaundice and serum bilirubin
testing was performed when deemed necessary by clinical
evaluation. Jaundice was classified according to Kramer
system.16 Blood and reticulocyte counting were also
performed in all G6PD-deficient jaundiced neonates and, when
necessary, the Coombs test was employed in order to detect
any materno-fetal alloimmunization. G6PD activity was
assayed in both parents.
Although the deficient neonates were not followed up
after hospital discharge, their mothers received an
identification card indicating G6PD deficiency and containing
basic information about the clinical trait, possible clinical
situations and a list of drugs and medicines which may trigger
hemolysis.
Results
Eight (3.9%) G6PD-deficient individuals were identified
among the 204 male newborns who participated in this study.
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The sample comprised newborns from 78 white women and
126 black women (Table 1); these figures are not
representative of the general population, as the aim of this
study was just to disclose the presence of jaundice in G6PD-
deficient male newborns.
Four out the eight newborns (50%) evolved with
jaundice within the first two days after birth, exhibiting
bilirubin levels higher than 10 mg/dL which affected dermal
zones 3 and 4 with progressive cephalo-pedal icterus (Table
2). Among the four deficient newborns who presented with
jaundice, only two had low hemoglobin levels (Table 3).
Interestingly one of them was positive for the direct Coombs
test and reticulocytosis, showing an association between
materno-fetal ABO blood group incompatibility and G6PD
deficiency.
All G6PD-deficient individuals presented the African
G6PD A- variant at electrophoresis. Their mothers showed
intermediary G6PD activity, except for one for whom it was
impossible to obtain a blood sample.
Discussion
In Brazil, several surveys have been carried out regarding
the populational prevalence of G6PD deficiency, but few have
studied the presence of jaundice in G6PD-deficient newborns.
In the current study, all G6PD-deficient individuals detected
by the screening test were subsequently checked by
quantitative spectrophotometric assay.
The African variant (G6PD A-)
observed in all G6PD-deficient
individuals reflects its high frequency
in Brazil. Other studies based on
electrophoretic mobility6,7,17 and DNA
analysis18 from deficient individuals
have confirmed the frequency of the
A- variant and low frequencies of the
Mediterranean variant.
Among the eight deficient
newborns, four presented with
jaundice with two of them also
exhibiting ABO alloimmune materno-
fetal incompatibility. All icteric
newborns were submitted to
phototherapy.
The G6PD-deficient newborn
who presented ABO incompatibility
also had a low hemoglobin level.
Although he had signs of hemolysis
(anemia, reticulocytosis and positive
direct Coombs test), he did not exhibit
bilirubin levels higher than the other
newborns with jaundice suggesting
that the combination of traits does not
express any additional hemolytic
effect as has previously been
reported.19 Another aspect about this
newborn is that he was identified by
the Brewer's test in spite of presenting
with reticulocytosis; it is well known
that reticulocytes, even in G6PD-
deficient individuals, exhibit higher
G6PD activity. Moderate G6PD
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deficiency of 3.8 IU is detected by the Brewer's screening
test, which helps to ascertain the etiology in many cases of
neonatal hyperbilirubinemia, thereby enabling early
interventions soon after the onset of jaundice. Moreover,
this warns neonatologists to prescribe non-oxidative drugs
for neonates as well as for their puerperal mothers as
maternal milk may contain the chemical agent. It is also
interesting to notice that the Brewer's test was able to detect
G6PD deficiency at a level of 6.0 IU.
The data obtained in the current work identified an
association between neonatal jaundice and the African G6PD
A-variant. This variant may present an inconclusive diagnosis
soon after a hemolytic crisis due to the high enzyme activity
found in reticulocytes.3 However a recent study reported
that the A-variant may be detected during a hemolytic crisis
even when there is low enzyme activity, thus a diagnosis is
possible.20 Neither low blood counts nor reticulocytosis was
observed in the G6PD-deficient individuals without ABO or
Rh blood group incompatibility.
Very recently new developments have been published
on the pathophysiology of neonatal jaundice in G6PD-
deficient individuals with several investigators believing that
hemolysis is not the cause of jaundice in G6PD-deficient
neonates.21,22,23 Indeed, the decreased ability of the neonate
liver to conjugate bilirubin seems to be the most important
factor, in particular when G6PD deficiency is coinherited with
mutations of UDP-glucuronosyltransferase 1 as in Gilbert
syndrome.20  Bacterial and viral infections, acidosis and
hypoxia seem to be other factors involved in neonatal
jaundice. The combination of G6PD deficiency and
prematurity is a risk factor that is highly associated with
severe hyperbilirubinemia and kernicterus. UDP-
glucuronosyltransferase presents increasing activity during
fetal development, and its decreased activity in premature
neonates leads to ineffective bilirubin conjugation that leads
to hyperbilirubinemia.12 Environmental factors such as
maternal exposure to oxidant drugs, herbal medicines and
naphthalene used in clothing may precipitate or exacerbate
neonatal jaundice in G6PD-deficient neonates.1,3
In this survey only full-term neonates were studied,
that is those from more than 37 weeks of gestation. No clinical
signs suggestive of infections, acidosis or hypoxia were
observed among the G6PD-deficient neonates who exhibited
jaundice. No oxidizing medicines that are associated with
jaundice, such as synthetic vitamin K or nitrites, were given
to the materno-fetal pair. All newborns were given natural
vitamin K. The mean G6PD activity in G6PD-deficient male
newborns was 2.9 ± 1.5 IU/gHb/min at 37°C. No correlation
was observed between enzyme activity and the severity of
the jaundice; although neonate nº 15 presented moderate
enzyme deficiency, severe hyperbilirubinemia was observed.
On the other hand, the bilirubin concentration was not so
high for neonate nº 61 who showed severe enzyme deficiency.
Interestingly, G6PD-deficient individuals who did not develop
jaundice exhibited the lowest G6PD activity. No correlation
has been observed between the levels of G6PD activity and
the presence of jaundice in any other published works.21
However, other investigators have demonstrated that enzyme
activity in G6PD deficient male newborns with hyper-
bilirubinemia is significantly lower than those without
hyperbilirubinemia.24 It was also observed that even in the
absence of putative hemolytic agents, these G6PD-deficient
individuals may present moderate jaundice.
This study demonstrated a high rate of jaundice among
G6PD deficient newborns, all of whom presented the African
A- variant.
Resumo
A deficiência de glicose-6-fosfato desidrogenase (G6PD) é a
anormalidade enzimática hereditária mais frequente. É transmitida
como caráter recessivo ligado ao cromossomo X e as principais
manifestações clínicas são hemólise induzida por fármacos,
icterícia neonatal e anemia hemolítica não esferocítica. O objetivo
do estudo foi determinar a presença de icterícia neonatal em recém-
nascidos do sexo masculino deficientes de glicose-6-fosfato
desidrogenase. Foram analisadas 204 amostras de sangue
umbilical de recém-nascidos do sexo masculino provenientes da
Maternidade Escola Januário Cicco em Natal, Rio Grande do
Norte. A deficiência da glicose-6-fosfato desidrogenase foi deter-
minada através do método qualitativo da redução da metahemo-
globina (teste de Brewer) e confirmada mediante determinação
espectrofotométrica quantitativa da atividade da G6PD e pela
eletroforese da enzima em acetato de celulose. Oito recém-nascidos
apresentaram deficiência da G6PD, e quatro deles exibiram
icterícia nas primeiras 48 horas depois do nascimento, com
valores de bilirrubina maiores de 10 mg/dL. Todos os deficientes
apresentaram a variante A-. Os dados encontrados confirmam a
associação da deficiência da G6PD e a icterícia neonatal. Assim
sendo, o diagnóstico precoce da deficiência logo após o nascimento
é essencial ao controle do aparecimento da icterícia e para evitar
o contato destes recém-nascidos com conhecidos agentes hemo-
líticos.
Palavras-chave: Glucosefosfato desidrogenase; recém-nascido;
icterícia neonatal; hiperbilirrubinemia.
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